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Background. Retrospective data suggest that cryptococcal antigen (CrAg) screening in patients with late-stage human immunode-
ﬁciency virus (HIV) initiating antiretroviral therapy (ART) may reduce cryptococcal disease and deaths. Prospective data are limited.
Methods. CrAg was measured using lateral ﬂow assays (LFA) and latex agglutination (LA) tests in 645 HIV-positive, ART-naive
patients with CD4 counts ≤100 cells/µL in Cape Town, South Africa. CrAg-positive patients were offered lumbar puncture (LP) and
treated with antifungals. Patients were started on ART between 2 and 4 weeks and followed up for 1 year.
Results. A total of 4.3% (28/645) of patients were CrAg positive in serum and plasma with LFA. These included 16 also positive by
urine LFA (2.5% of total screened) and 7 by serum LA (1.1% of total). In 4 of 10 LFA-positive cases agreeing to LP, the cerebrospinal
ﬂuid (CSF) CrAg LFA was positive. A positive CSF CrAg was associated with higher screening plasma/serum LFA titers.
Among the 28 CrAg-positive patients, mortality was 14.3% at 10 weeks and 25% at 12 months. Only 1 CrAg-positive patient, who
defaulted from care, died from cryptococcal meningitis (CM). Mortality in CrAg-negative patients was 11.5% at 1 year. Only 2 possible
CM cases were identiﬁed in CrAg-negative patients.
Conclusions. CrAg screening of individuals initiating ART and preemptive ﬂuconazole treatment of CrAg-positive patients resulted
in markedly fewer cases of CM compared with historic unscreened cohorts. Studies are needed to reﬁne management of CrAg-positive
patients who have high mortality that does not appear to be wholly attributable to cryptococcal disease.
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Cryptococcal meningitis (CM) is a leading cause of death in
late-stage human immunodeﬁciency virus (HIV)–infected pa-
tients in much of the developing world [1–5]. In many low-
resource settings, patients with advanced immunosuppression
continue to present late to antiretroviral therapy (ART) treat-
ment programs, and many die of HIV-related illness in the
weeks just prior to and months following initiation of ART. CM
causes many of these deaths and is also a heavy burden on
healthcare facilities [6–11]. CM treatment remains inadequate,
with an acute mortality ranging from 25% to more than 50%
with current antifungal therapies [12].
Many of these CM cases may be preventable. Retrospective
data have shown that routine screening for cryptococcal antigen
(CrAg) to detect subclinical disease in patients presenting to
ART programs can identify which patients are at risk of devel-
oping CM [13, 14]. Once identiﬁed, these patients could then
be given preemptive treatment with high-dose ﬂuconazole to
prevent them from developing severe disease [15]. This strategy
is likely to be cost-effective [16–18] and has been endorsed in
World Health Organization guidelines [19] and adopted by
some African countries [20].
However, despite early programmatic rollout, prospective
data on the implementation and efﬁcacy of screening are limit-
ed, as are data to guide how best to manage patients who test
antigen positive. We undertook a prospective study of screening
for CrAg in the plasma, serum, and urine of patients with late-
stage HIV infection who enrolled for ART at 2 clinics in Cape
Town, South Africa.
METHODS
Participants and Procedures
Consecutive, HIV-positive, ART-naive patients with no prior his-
tory of cryptococcal disease, aged >18 years, and with a CD4 cell
count ≤100 cells/µL presenting to 2 ART clinics in Cape Town
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between May 2011 and April 2014 were approached for enroll-
ment. Consenting patients were screened for CrAg with the lat-
eral ﬂow assay (LFA; IMMY, Norman, Oklahoma) using serum,
plasma, and urine samples. The ﬁnal 192 patients recruited also
had an LFA performed on whole blood. At completion of recruit-
ment, we determined CrAg titers on stored serum, plasma, and
urine samples from patients who screened positive for CrAg
using the CrAg LFA-IMMY kit, as per manufacturer’s instruc-
tions. Serum was also tested using the latex agglutination assay
(LA; CALAS system, Meridian Biosciences, Cincinnati, Ohio).
At the start of the study, the LFA was not approved (neither
conformite Europeenne marked nor US Food and Drug Admin-
istration approved), and the initial 150 patients screened were
treated on the basis of the LA test result; the test had also been
used to demonstrate that screening identiﬁes those at risk, and
not at risk, of clinical cryptococcal disease [7]. During this period,
LA-negative but LFA-positive patients received no antifungal
therapy. As soon as it became clear that a signiﬁcant number of
patients were positive by LFA but not by LA, a protocol amend-
ment wasmade to enable antifungal therapy to be given to patients
who tested positive by either test.
Patients positive for CrAg were questioned and examined for
symptoms and signs of meningitis. They had blood cultures per-
formed and were offered a lumbar puncture (LP) to exclude early
subclinical CM. Patients with evidence of meningeal involvement
on the basis of positive cerebrospinal ﬂuid (CSF) CrAg-LFAwere
admitted for intravenous amphotericin followed by ﬂuconazole,
as per local guidelines [12]. Those with negative CSF CrAg or de-
clining LP were started on oral ﬂuconazole: 800 mg daily for 2
weeks, 400 mg daily for 8 weeks, and 200 mg daily thereafter.
All patients were started on efavirenz-based ART 2–4 weeks
after CrAg screening, as per local guidelines. Patients on rifam-
picin had the dose of ﬂuconazole increased by 50%.
Patients who screened CrAg positive were followed up every 2
weeks for 10 weeks and every 3 months thereafter for the ﬁrst
year of ART. Those screening CrAg negative were seen by clinic
staff, and prospective data were collected every 3 months for the
ﬁrst year of ART. Telephone follow-up and home visits were un-
dertaken for missed visits. Follow-up data were also collected
using the National Health Laboratory Service electronic database,
the Department of Home Affairs death register, and the provincial
government electronic database systems. CrAg-negative patients
were cross-referenced with the National Institute for Communi-
cable Diseases’ national surveillance GERMS South Africa data-
base (http://www.nicd.ac.za/?page=germs-sa&id=97) to detect
cases of CM diagnosed outside the Western Cape province .
The research ethics committees of the University of Cape
Town and St. George’s University of London approved the
study. All participants gave written informed consent.
Outcomes
The primary clinical outcome measure was incidence of CM
in the ﬁrst year of ART in all screened patients. Secondary
outcomes were time to ART in CrAg-positive and CrAg-negative
patients, the proportion of CrAg-positive patients who devel-
oped cryptococcal immune reconstitution inﬂammatory syn-
drome, and all-cause mortality.
The primary laboratory outcome measure was the prevalence
of cryptococcal antigenemia. Secondary outcomes were the
concordance of the serum LA CrAg test; the serum, plasma,
whole blood, and urine LFA CrAg tests; and the relationship
of antigen titer to CSF ﬁndings.
Statistical Analyses
Data were analyzed using Stata (v. 13, StataCorp). Variables
were compared using Pearson χ2, Fisher exact, and Wilcoxon
rank-sum tests as appropriate. One-year survival was compared
using Cox proportional hazards regression models, adjusting
for age, sex, and CD4 cell count, and Kaplan–Meier survival
curves.
RESULTS
A total of 670 patients were screened, of whom 645 met eligibil-
ity criteria and consented (Figure 1).
Cryptococcal Antigen Prevalence
Twenty-eight of the 645 patients (4.3%) screened were CrAg
positive using the LFA in plasma and serum, and these results
were 100% concordant. Seven of these patients (1.1% of those
screened) were also positive by LA; all patients with a positive
serum LA had a positive LFA. No signiﬁcant baseline clinical or
laboratory differences were identiﬁed between CrAg-positive
and CrAg-negative patients (Table 1).
Cryptococcal Antigenemia in Urine and Whole Blood
Fifty-seven percent (16 of 28 patients) with a positive serum/
plasma LFA had a positive urine LFA. An additional 16 serum/
plasma LFA-negative patients also tested positive with the urine
LFA. These were considered false positives. On repeat testing of
the same urine samples after freezing at −80°C, 12 of the 16 false-
positive urine samples were LFA negative, leaving 4 unresolved
false-positive urine LFA results.
LFA testing of whole blood from 192 patients, including 8 with
a positive serum/plasma CrAg, demonstrated 100% concordance
between the LFA results from whole blood and serum/plasma.
Cryptococcal Antigen Titres
Serial dilutions were performed to determine CrAg titers in
serum, plasma, and urine in those screening CrAg positive (see
Supplementary Figure 1). There was 100% agreement between
serum and plasma titers. There was no agreement between visual
LFA CrAg grading performed according to manufacturer’s in-
structions (grades 1–5) and antigen titer. Having a positive
serum LA test was associated with higher LFA titers in plasma/
serum and urine samples. On average, titers were 2 dilutions
lower in urine compared with the corresponding plasma or
serum samples.
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Proportion of Patients CrAg-Positive by LFA in Blood With Evidence of
Meningeal Involvement
Ten of 28 patients with a positive serum/plasma LFA test con-
sented to LP. Forty percent (4 of 10) were CSF CrAg LFA pos-
itive (Table 2). Having a positive CSF CrAg was associated
with higher serum/plasma LFA titers (see Supplementary Fig-
ure). There were no cases with a positive CSF CrAg with a titer
lower than 1:160 in the serum/plasma. All 4 CSF CrAg positive
cases were also positive by LFA in urine, with titers greater
than 1:20. Three of 4 patients with a positive CSF CrAg were
positive by LA in serum. In this small sample, headache and
fever were not helpful in distinguishing between patients
with and without positive CSF CrAg (Table 2). Patients with
a positive CSF CrAg usually had other CSF evidence of meningeal
Figure 1. Flow of patients from study inclusion through to discharge. Abbreviations: ART, antiretroviral therapy; CM, cryptococcal meningitis; CrAg, cryptococcal antigen;
CSF, cerebrospinal fluid; LA, latex agglutination assay; LFA, lateral flow assay; LP, lumbar puncture; LTFU, lost to follow up.
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involvement, for example, positive India ink or culture results or
raised CSF protein (Table 2).
Treatment of CrAg-Positive Patients and Outcomes
The 4 patients diagnosed with CM on the basis of a positive CSF
CrAg were treated with amphotericin B for a median of 14 days,
followed by ﬂuconazole. Of these 4 patients, 2 died in the ﬁrst 10
weeks and 1 died 6 months later. Two patients died prior to
starting ART. Time to ART for the other patients was 20 days
and 26 days. None of these deaths were directly attributable to
CM, although CM-IRIS could not be ruled out in 1 case (see
Supplementary Table 1).
Of the remaining 24 serum/plasma CrAg-positive patients,
7 were identiﬁed as LFA positive/LA negative prior to LFA
approval and were therefore not treated with ﬂuconazole. Six
of these patients were started on ART (median time to ART,
3.1 weeks; interquartile range [IQR], 2–9.1). All 6 were alive
at 1 year and none developed CM. The remaining LFA
CrAg-positive–LA CrAg-negative patient defaulted all fol-
low-up and died of CM 3 months later, having never initiated
ART. Seventeen patients treated on the basis of the positive
LFA result (4/17 also LA positive), known to have a negative
CSF CrAg or who declined LP, were treated with ﬂuconazole.
In these patients, ART was started at a median of 2.9 weeks
(IQR, 2–4). Two of these patients had died by 10 weeks and
3 had died by 12 months. None of these deaths were attributed
to CM (see Supplementary Table 1).
Outcomes were ascertained for all 28 CrAg-positive patients.
Mortality was 14.3% (4/28) at 10 weeks and 25% (7/28) at 12
months. Other than the 4 patients with proven CSF antigenemia
at baseline, no CrAg-positive patients who were prescribed ﬂu-
conazole and ART went on to develop CM. No patients with
proven CSF antigenemia at baseline developed cryptococcal
IRIS, with the possible exception of case 3 (see Supplementary
Table 1).
Table 1. Baseline Patient Characteristics
Variable All Patients (n = 645) CrAg Negative (n = 617) CrAg Positive (n = 28) P Value
Male (%) 302 (47%) 289 (45.7%) 13(46.4%) .97
Age, y (median [IQR]) 36 (31–42) 36 (31–42) 38.5 (32–43.5) .26
CD4 count, cells/mm3 (median [IQR]) 55.5 (28–78) 56 (29–78) 49 (14–90) .48
Hemoglobin, g/L (median [IQR]) 10.9 (9–12.3) 10.7 (8.9–12.3) 10.65 (9.35–12.55) .65
White blood cell count, cells × 109/mm3 (median [IQR]) 5.07 (3.84–6.82) 5.09 (3.84–6.85) 5.05 (3.97–6.12) .66
Creatinine, µmol/L (median [IQR]) 68 (58–83) 68 (57–83) 66.5 (58–85) .81
Alanine transaminase, IU/L (median [IQR]) 26 (18–41) 26 (18–41) 24 (17–40) .63
Abbreviations: CrAg, cryptococcal antigen; IQR, interquartile range.
Table 2. Comparison of Serum Cryptococcal Antigen (CrAg)–Positive Patients With a Positive Cerebrospinal Fluid (CSF) CrAg, Negative CSF CrAg, or Those
Who Declined to Have an Lumbar Puncture
Symptom CSF CrAg+ (n = 4) CSF CrAg− (n = 6) No Lumbar Puncture (n = 18)
Headache 1/4 3/6 2/18
Fever 2/4 1/6 2/18
Confusion 0/4 1/6 1/18
CrAg testing
Serum latex agglutination assay positive 3/4 1/6 3/18
Urine lateral flow assay positive 4/4 3/6 9/18
CSF parameters
CSF CrAg titers (n = 3) Neat, 40, >2560 NA NA
India ink positive 3/4 0/6 NA
CSF culture positive 2/3a 0/6 NA
CSF protein, g/L (n raised [median]) 2/4 (0.54) 0/5(0.21) NA
CSF glucose (n <50% of serum [median]) 2/4(2.5) 1/5(3) NA
CSF white blood cell count (range), cells/mm3 0–1 0–2 NA
Blood culture
Positive for Cryptococcus neoformans 2/4 0/6 0/18
Mortality
10 wk 2/4 1/6 1/18
6 mo 3/4 1/6 3/18
1 y 3/4 1/6 3/18
Abbreviations: CrAg, cryptococcal antigen; CSF, cerebrospinal fluid; NA, not applicable.
a One patient did not have CSF cultured due to laboratory error, hence 2/3 rather than 2/4.
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Treatment of CrAg-Negative Patients and Outcomes
CrAg-positive patients had a signiﬁcantly higher risk of death
than CrAg-negative patients over the ﬁrst year on ART (hazard
ratio [HR] for death = 2.46; 95% conﬁdence interval [CI], 1.13–
5.36; P = .023; Figure 2). Of the 617 patients who were CrAg
negative on serum/plasma LFA testing, mortality was 5.3%
(n = 32) at 10 weeks and 11.5% (n = 71) at 1 year. Eight patients
were lost to follow-up, and the remaining 539 were alive at 1
year. This mortality difference remained highly signiﬁcant
after adjustment for age, sex, and CD4 count (adjusted
HR = 2.44; 95% CI, 1.12–5.32; P = .024). Presumed causes of
death in the CrAg-negative patients are shown in Table 3;
23% of deaths were of unknown cause. In none of these un-
known cases was cryptococcal disease suspected.
One deﬁnite case and one possible case of cryptococcal disease
were identiﬁed in patients who screened CrAg negative: 1 patient
started ART 10 days after screening and was virally suppressed at
week 28 with a good CD4 cell recovery (40 cells/µL at baseline,
140 cells/µL at week 28). The patient developed conﬁrmed dis-
seminated tuberculosis at week 29 and started anti-tuberculosis
treatment. He was admitted to the hospital at week 31 with sei-
zures and a stroke. CSF was reported as protein >5 g/L, glucose
0.3 mmol/L, lymphocytes 57 cells/µL, CrAg positive, and India
ink and culture negative. CSF was not cultured forMycobacterium
tuberculosis, and no peripheral CrAg was done. Amphotericin B
followed by ﬂuconazole were added to anti-tuberculosis therapy,
and the patient made a good recovery. In retrospect, it was unclear
whether this was cryptococcal or tuberculous meningitis with
false-positive CSF CrAg. A second CrAg-negative patient was ad-
mitted to the hospital on day 364 of the study with CrAg and
Cryptococcus neoformans culture-positive CSF. That patient had
had poor adherence to ART (week 48 viral load 268 000 copies/
mL, CD4 207 cells/µL) and had defaulted clinic follow-up.
DISCUSSION
In this prospective study of patients with low CD4 counts initiat-
ing ART in South Africa, CrAg screening and preemptive ﬂucon-
azole treatment of CrAg-positive patients was associated with
markedly fewer cases of and deaths from CM compared with his-
toric unscreened cohorts. In a historic control cohort from one of
the study clinics, 28% of LA CrAg-positive patients who did not
receive preemptive antifungal therapy went on to develop proven
CM [7]. Our ﬁndings in this study suggest that preemptive anti-
fungal therapy and timely ART initiation prevents CrAg-positive
patients without meningeal involvement from developing CM or
CM-IRIS in the ﬁrst year of ART. Our results also conﬁrm ﬁnd-
ings from earlier studies [13, 21] that showed that the large ma-
jority of patients screen CrAg negative (>95% in this cohort) and
are not at signiﬁcant risk of clinical cryptococcal disease if ART is
started promptly after screening and if patients adhere. Impor-
tantly, screening did not lead to delays in ART initiation or de-
creased retention in care.
However, although cryptococcal disease was thought to be re-
lated to just 2 of 78 (2.6%) deaths in the ﬁrst year of ART (both
of these cases in patients who were nonadherent to ART) com-
pared with up to 20% of deaths in historic, unscreened cohorts
[6–8, 22], the mortality of CrAg-positive patients remained sig-
niﬁcantly higher than that of CrAg-negative patients, even after
adjustment for CD4 count and despite preemptive antifungal
therapy. This is consistent with data from other recently pub-
lished prospective CrAg screening studies [23–25].One possible
explanation is that the CrAg-positive patients were dying of un-
diagnosed cryptococcal disease; however, all patients were
closely followed up by the study team and alternative causes
of death were ascertained (see Supplementary Table 1). Another
Table 3. All-Cause Mortality of Cryptococcal Antigen (CrAg)–Positive
and CrAg-Negative Patients
Cause of Deatha
CrAg
Negative
CrAg
Positive Total
Tuberculosis pulmonary/tuberculosis
undefined
27 0 27
Tuberculosis extra-pulmonary 5 1 6
Tuberculosis IRIS 3 0 3
Sepsis, all cause 13 2 15
Renal failure 1 1 2
Measles 1 0 1
Colonic cancer, metastatic 0 1 1
Cytomegalovirus encephalitis/hepatitis 1 0 1
Toxoplasmosis 1 0 1
Varicella Zoster Virus meningitis 1 0 1
Cryptococcal meningitis 1 1 2
Unknown 17 1 18
Total 71 7 78
Abbreviations: CrAg, cryptococcal antigen; IRIS, immune reconstitution inflammatory
syndrome.
a Cause of death was ascertained where possible using electronic databases, death
certificate data, and patient hospital notes review.
Figure 2. Kaplan–Meyer survival curves showing survival over time in patients
screening cryptococcal antigen (CrAg) positive with lateral flow assay (n = 28) com-
pared with those screening CrAg negative (n = 617). Abbreviation: LFA, lateral flow
assay.
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explanation is that the CrAg-positive patients are also at in-
creased risk of dying from other AIDS-related conditions [26,
27].Cryptococcal antigen itself has signiﬁcant immunosuppres-
sive effects [28], providing one possible explanation for these
observations. Another is that CrAg positivity is a marker of pro-
foundly impaired immunity (not adequately reﬂected by the
CD4 count alone). Differences in host genetics may determine
why some patients, despite presumed widespread exposure to
Cryptococcus, develop disseminated infection and others do
not. Such differences may also be reﬂected in increased suscept-
ibility to additional opportunistic infections and AIDS-related
malignancies.
The cryptococcal LFA yielded 4-fold more positive samples
compared with the LA, conﬁrming its signiﬁcantly higher sen-
sitivity [29, 30]. It was also shown to perform well on whole
blood samples, meaning true point-of-care screening should
be possible using ﬁnger prick blood samples [31]. Unfortunate-
ly, in asymptomatic or minimally symptomatic patients, the
sensitivity of the LFA using urine was low (57% relative to
serum/plasma), and more problematically, there were as many
false-positive as true-positive results, yielding a 50% positive
predictive value in this context. This conﬁrms other recent re-
ports that showed low sensitivity of urine LFA when used to
screen patients initiating ART and false-positive results [32].
The LFA is not approved for use with urine and, on the basis
of these ﬁndings, cannot be recommended for screening asymp-
tomatic individuals. Positive urine samples must be conﬁrmed
by testing another approved specimen type.
Interestingly, the prevalence of asymptomatic antigenemia
was lower than predicted (4.3% with sensitive LFA and only
1.1% with the LA). In comparison, the antigen prevalence was
6% using the LA in a cohort with CD4 cell counts ≤100 cells/µL
and no prior cryptococcal meningitis drawn from the same pa-
tient population between 2002 and 2005 [13]. Similar results are
seen in current screening data from Gauteng who detected 4%
CrAg prevalence using the LA in 2009–2010 and 4% more re-
cently using the LFA [33, 34]. Reasons for this reduction in
CrAg prevalence in the patient group with a CD4 cell count
≤100 cells/µL are not clear. The risk of reactivation of or new
infection with C. neoformans is likely to be related to the dura-
tion of severe immunosuppression; current patients with a CD4
cell count <100 cells/µL in South Africa may not have been at
this level of immunosuppression for as long as patients in
prior years due to improvements in ART provision and access
[23]. It will be important to see if reductions in antigen preva-
lence occur in other centers and countries over time, as the cost-
effectiveness of CrAg screening interventions are related to
CrAg prevalence in the screened population [16].
Meningeal involvement was present in 40% of patients
screening CrAg positive who consented to LP, even in the ab-
sence of marked symptoms. However, it would be difﬁcult to
routinely offer LPs to all patients who screen CrAg positive in
African ART programs. Of the 11 CrAg-positive patients who
declined LP but took ﬂuconazole, 4 had a serum titer ≥1:160
and none developed CM, providing preliminary evidence that
high-dose ﬂuconazole plus ART is sufﬁcient to prevent the de-
velopment of clinical CM in the majority of cases. Whether or
not LPs are required to guide management in asymptomatic
CrAg-positive patients remains to be determined, but meninge-
al involvement in this study was associated with higher antigen
titers, raising the possibility that lumbar punctures and/or more
aggressive antifungal therapy could be targeted to those with
higher antigen titers.
Our study provides important new prospective data to inform
CrAg screening interventions in patients with low CD4 cell
counts entering ART programs. However, optimal strategies
for implementing screening still need to be deﬁned. The very
high mortality in CrAg-positive patients despite antifungal
therapy suggests that CrAg screening may be best implemented
as part of a combined opportunistic infection (OI) screening
and intervention package for patients in this high-risk group.
Further work is needed to better understand the persisting
high mortality and how best to incorporate screening for CM
and other OIs into routine care pathways.
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